SynthesisObesity surgery2026
Effectiveness of Transoral Outlet Reduction Post-Roux-en-Y Gastric Bypass Beyond the One-Year Benchmark: A Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransoral outlet reduction (TORe) is increasingly performed for recurrent weight gain or suboptimal clinical response after Roux-en-Y gastric bypass (RYGB). However, the durability of outcomes beyond one year remains uncertain.
methodsA systematic review and meta-analysis was conducted following PRISMA guidelines. Six databases were searched to June 2025 for RCTs and cohort studies of adults undergoing TORe after RYGB with ≥ 12 months of follow-up. Outcomes included % total weight loss (%TWL), % excess weight loss (%EWL), and adverse events (AEs). Data were pooled using random effects restricted maximum likelihood models.
resultsTwenty-five studies (3 RCTs, 22 observational; 2667 patients) were included. Pooled baseline age was 47.3 years, 86.0% were female, mean BMI was 38.0 kg/m², and mean interval from RYGB to TORe was 9.5 years. At 12 months, pooled %TWL was 8.0% (95% CI 6.3-9.7) and pooled %EWL was 20.3% (95% CI 14.1-26.5). Weight loss declined at longer follow-up, with pooled estimates of 7.7% TWL and 16.3% EWL at 24 months, and 4% TWL at 36 months. In meta-regression, years since RYGB predicted greater %TWL and %EWL. The pooled AE rate was 5% (95% CI 3-7%), and the pooled SAE rate was 0.3% (95% CI 0.1-0.5%), with no procedure-related mortality.
conclusionTORe can provide modest but clinically meaningful weight loss at 12 months with a low rate of serious AE although durability beyond two years appears limited. It may be best regarded as an anatomically corrective intervention that is most effective when incorporated into comprehensive, long-term obesity management.
Indexed as
Identifiers
41483042What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.